Issue 3, August 2011
Identifying Comorbidities in Patients with Fibromyalgia
Release Date: August-05-11
Credit Expiration Date: August-06-12
This activity is jointly sponsored by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
This interactive newsletter series is designed to meet the needs of primary care physicians and other providers who care for patients with fibromyalgia.
An interactive CME-certified interactive newsletter series on the recognition, diagnosis, and treatment of fibromyalgia in the primary care setting.
This newsletter focuses on the major symptoms and conditions that accompany the fibromyalgia syndrome (FMS) with frequencies that exceed their prevalence in the general population. Conditions include chronic widespread pain, chronic insomnia, affective disorders, fatigue, dyscognition, headache, irritable bowel syndrome, interstitial cystitis, autonomic dysfunction, restless leg syndrome, and nocturnal leg cramps. Understanding these comorbidities of FMS is important because they contribute to the misery experienced by affected patients and increase the likelihood that these individuals will eventually become dysfunctionally impaired.
The comorbidities associated with fibromyalgia further complicate the diagnosis and management of this condition, so primary care providers must know how to recognize these comorbidities in order to properly manage patients. Primary care clinicians play a critical role in educating and guiding patients through their illnesses. Becoming more familiar with fibromyalgia and its related conditions will help clinicians and their patients develop an integrative approach to symptom management.
Jon Russell, MD, PhD, ACR Master
Retired Faculty, The University of Texas Health Science Center at San Antonio
Editor, Journal of Musculoskeletal Pain
Emeritus Founding President of the International MYOPAIN Society
Medical Director, Fibromyalgia Research and Consulting
Current Affiliation, Arthritis and Osteoporosis Center of South Texas
San Antonio, TX
Peter Barland, MD (CCME Reviewer)
Professor Emeritus, Departments of Medicine and Pathology
Albert Einstein College of Medicine of Yeshiva University
New York, NY
We would like to thank Jane Barbosa Ayala, MD, of the Arthritis & Osteoporosis Center of South Texas; San Antonio, TX, for granting us permission to use materials that belong to her as part of this presentation.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine of Yeshiva University requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine of Yeshiva University and Medical Communications Media, Inc. staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Albert Einstein College of Medicine of Yeshiva University also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.
Dr. Russell discloses that he has served as a consultant for Jazz Pharmaceuticals and Johnson & Johnson, served on the speakers' bureau for Eli Lilly & Co., and received research funding from Pfizer, Inc.
Dr. Barland has no disclosures.
The staff of CCME of Albert Einstein College of Medicine of Yeshiva University have no disclosures to report with any commercial interests other than the following:
Steven Jay Feld, or a member of his household own securities in: Bioheart, Inc., Chelsea Therapeutics, Inc. and Pharmacopeia, Inc.
Kathleen Hines (MCM, Inc. medical editor) has no disclosures.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center and Medical Communications Media, Inc. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 60% or better on the post-test.
This activity will take approximately 30 minutes to complete.
This activity is supported by educational grants from Pfizer, Inc. and Forest Laboratories, Inc.
Presented by Albert Einstein College of Medicine of Yeshiva University & Montefiore Medical Center, Center for Continuing Medical Education, the National Fibromyalgia Association, and Medical Communications Media, Inc.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine of Yeshiva University & Montefiore Medical Center, Center for Continuing Medical Education, the National Fibromyalgia Association, Forest Laboratories, Inc., or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.